GB0607952D0 - Novel treatment - Google Patents

Novel treatment

Info

Publication number
GB0607952D0
GB0607952D0 GBGB0607952.9A GB0607952A GB0607952D0 GB 0607952 D0 GB0607952 D0 GB 0607952D0 GB 0607952 A GB0607952 A GB 0607952A GB 0607952 D0 GB0607952 D0 GB 0607952D0
Authority
GB
United Kingdom
Prior art keywords
novel treatment
novel
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0607952.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MINSTER RES Ltd
Original Assignee
MINSTER RES Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MINSTER RES Ltd filed Critical MINSTER RES Ltd
Priority to GBGB0607952.9A priority Critical patent/GB0607952D0/en
Publication of GB0607952D0 publication Critical patent/GB0607952D0/en
Priority to CA002649590A priority patent/CA2649590A1/en
Priority to CNA2007800232331A priority patent/CN101472586A/zh
Priority to US12/226,423 priority patent/US20090318414A1/en
Priority to PCT/GB2007/001463 priority patent/WO2007125287A1/en
Priority to EP07732503A priority patent/EP2012783A1/en
Priority to JP2009505965A priority patent/JP2009534367A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0607952.9A 2006-04-21 2006-04-21 Novel treatment Ceased GB0607952D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0607952.9A GB0607952D0 (en) 2006-04-21 2006-04-21 Novel treatment
CA002649590A CA2649590A1 (en) 2006-04-21 2007-04-23 Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
CNA2007800232331A CN101472586A (zh) 2006-04-21 2007-04-23 用m1/m4毒蕈碱激动剂(沙可美林)治疗前驱综合症的单独和联合疗法
US12/226,423 US20090318414A1 (en) 2006-04-21 2007-04-23 Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome
PCT/GB2007/001463 WO2007125287A1 (en) 2006-04-21 2007-04-23 Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
EP07732503A EP2012783A1 (en) 2006-04-21 2007-04-23 Mono and combination therapy with m1/m4 muscarinic agonist (sabcomeline) for treatment of prodromal syndrome
JP2009505965A JP2009534367A (ja) 2006-04-21 2007-04-23 前駆症状症候群の治療にｍ１／ｍ４ムスカリン性アゴニスト（サブコメリン）を用いる単独及び組合せ療法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0607952.9A GB0607952D0 (en) 2006-04-21 2006-04-21 Novel treatment

Publications (1)

Publication Number Publication Date
GB0607952D0 true GB0607952D0 (en) 2006-05-31

Family

ID=36581049

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0607952.9A Ceased GB0607952D0 (en) 2006-04-21 2006-04-21 Novel treatment

Country Status (7)

Country Link
US (1) US20090318414A1 (enExample)
EP (1) EP2012783A1 (enExample)
JP (1) JP2009534367A (enExample)
CN (1) CN101472586A (enExample)
CA (1) CA2649590A1 (enExample)
GB (1) GB0607952D0 (enExample)
WO (1) WO2007125287A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
PL3134386T3 (pl) 2014-04-23 2020-11-16 Takeda Pharmaceutical Company Limited Pochodne izoindolin-1-onu jako dodatnia aktywność allosterycznego modulatora cholinergicznego receptora muskarynowego m1 do leczenia choroby alzheimera
TN2017000508A1 (en) 2015-06-26 2019-04-12 Takeda Pharmaceuticals Co 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
JP6787913B2 (ja) 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
JP7096441B2 (ja) 2018-09-28 2022-07-05 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48315A1 (en) * 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
GB0008921D0 (en) * 2000-04-11 2000-05-31 Smithkline Beecham Plc Method of treatment
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
EP1299352B1 (en) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
WO2003057672A2 (en) * 2001-12-28 2003-07-17 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
GB0428180D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Combination therapy

Also Published As

Publication number Publication date
CA2649590A1 (en) 2007-11-08
CN101472586A (zh) 2009-07-01
US20090318414A1 (en) 2009-12-24
WO2007125287A1 (en) 2007-11-08
JP2009534367A (ja) 2009-09-24
EP2012783A1 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
PL2043944T3 (pl) Maszyna do obróbki
GB0711342D0 (en) Well treatment
GB0624874D0 (en) Treatment
GB0600692D0 (en) Well treatment
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
GB0716784D0 (en) Well treatment
GB0516068D0 (en) Well treatment
GB0511769D0 (en) Treatment
GB0525540D0 (en) New treatment
GB0607952D0 (en) Novel treatment
GB0604460D0 (en) Treatment
GB0621229D0 (en) Novel use
AP2009004788A0 (en) Novel use
GB0502171D0 (en) Well treatment
GB0610431D0 (en) Treatment
GB0605781D0 (en) Treatment
GB0602857D0 (en) The treatment of sialorrhoea
GB0617865D0 (en) Novel use
GB0603087D0 (en) Novel use
GB0605931D0 (en) Endoscope
GB0724838D0 (en) Effulent treatment
GB0710732D0 (en) Treatment
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
GB0603430D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)